NephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for NDI

Learn more about the recently announced collaboration between NephroDI Therapeutics, The McQuade Center for Strategic Research and Development, LLC (MSRD), and Otsuka.

Nephrogenic diabetes insipidus (NDI) is a rare genetic condition that affects children.

NephroDI's co-founders have identified a novel series of AMPK as a potential therapy for Nephrogenic diabetes insipidus (NDI).

Lack of concentration is our focus.

NephroDI Therapeutics is a pharmaceutical company focusing on concentration disorders of the kidney. NephroDI is initially developing an oral drug to treat Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan disease.

Learn more about NephroDI

We’re addressing unmet challenges

Patients suffering from NDI  produce up to 20 liters (or 5 gallons) of  urine per day due to an inability of the kidney to concentrate urine normally in response to the hormone vasopressin.  Congenital NDI in children is caused by mutations in a vasopressin receptor gene located on the X chromosome. Congenital NDI has a profound impact on children because they must drink up to 20 liters of water per day to avoid severe dehydration. Children who suffer multiple episodes of severe dehydration often end up with mental retardation.  Also, children that try to hold their urine frequently suffer from progressive kidney damage.

More information about NDI can be found here.